{"data":{"id":868,"lang":"en","title":"Cancer Drug Injected Into One Tumor Makes Others Vanish Across the Body in Rockefeller Trial","summary":"Engineered CD40 drug 2141-V11 injected into one tumor triggered body-wide cancer shrinkage in 50% of patients, with two in complete remission.","category":"science","category_label":"Science","published_at":"2026-03-18T01:02:25Z","updated_at":"2026-03-18T01:02:25Z","url":"https://techtools.cz/tools/news/article/868-cancer-drug-injected-into-one-tumor-makes-others-vanish-across-the-body-in","api_url":"https://techtools.cz/news-api/v1/articles/868?lang=en","markdown_url":"https://techtools.cz/news-api/v1/articles/868.md?lang=en","image_url":"https://www.rockefeller.edu/news/uploads/www.rockefeller.edu/sites/13/2025/08/Ravetch_HERO_080525.jpg","word_count":161,"reading_time_minutes":1,"sources":[{"url":"https://www.rockefeller.edu/news/38120-immunotherapy-drug-eliminates-aggressive-cancers-in-clinical-trial/","domain":"rockefeller.edu"},{"url":"https://www.sciencedaily.com/releases/2026/03/260315225121.htm","domain":"sciencedaily.com"}],"translation":{"lang":"cs","id":895,"title":"Lék na rakovinu vstříknutý do jednoho nádoru způsobil zmizení ostatních nádorů v celém těle","url":"https://techtools.cz/tools/news/clanek/895-lek-na-rakovinu-vstriknuty-do-jednoho-nadoru-zpusobil-zmizeni-ostatnich-nadoru","api_url":"https://techtools.cz/news-api/v1/articles/895?lang=cs"},"content":"An engineered immunotherapy drug called 2141-V11 shrank tumors in half of patients with metastatic cancer when injected directly into a single tumor, with two achieving complete remission. Developed by Jeffrey V. Ravetch at Rockefeller University, the drug activates CD40 receptors on immune cells, triggering a body-wide anti-cancer response — even in tumors that were never injected.\n\nPrevious CD40 agonist antibodies showed promise in animal models but caused dangerous inflammation and liver toxicity when given intravenously. The breakthrough was twofold: Ravetch's team re-engineered the antibody to be 10 times more potent, and switched to direct tumor injection, which eliminated severe side effects. The drug creates tertiary lymphoid structures — immune cell clusters resembling lymph nodes — inside tumors, essentially turning them into immune training grounds.\n\nNearly 200 patients are now enrolled in expanded Phase 1/2 trials at Memorial Sloan Kettering and Duke University, testing the drug against bladder cancer, prostate cancer, and glioblastoma. Results from the initial 12-patient trial were published in Cancer Cell."}}